GILD Gilead Sciences
- 73.660
- -1.930-2.55%
- 73.700
- +0.040+0.05%
Gilead Sciences News
Gilead Sciences: A Cautious Hold Amidst Mixed Performance and Future Uncertainties
Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?
About 73% of the S&P 500 Names Beat on EPS During the Week - Earnings Scorecard
12 Out of 17 Healthcare Companies Beat Profit Estimates This Week- Earnings Scorecard
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
Express News | RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
Express News | Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Express News | Gilead Sciences Shares Are Trading Lower. The Company Reported Q2 Financial Results
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
Deutsche Bank Keeps Their Hold Rating on Gilead Sciences (GILD)
Express News | Gilead Sciences Inc. : Morgan Stanley Raises Target Price to $79.00 From $74.00
Gilead Sciences (GILD) Gets a Hold From Cantor Fitzgerald
Gilead Sciences: Hold Rating Affirmed Amid Mixed Performance and Cautious Outlook
Gilead Sciences Is Maintained at Outperform by BMO Capital
Gilead Sciences Analyst Ratings
Express News | Gilead : BMO Raises Target Price to $85 From $80
Morgan Stanley Raises Price Target on Gilead Sciences to $79 From $74, Keeps Equalweight Rating
Analysis
Price Target
No Data
